We serve Chemical Name:N-[(1-methylpyrrolidin-3-yl)methyl]ethanamine CAS:959239-24-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:N-[(1-methylpyrrolidin-3-yl)methyl]ethanamine
CAS.NO:959239-24-8
Synonyms:N-[(1-methylpyrrolidin-3-yl)methyl]ethanamine
Molecular Formula:C8H18N2
Molecular Weight:142.24200
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:175.3ºC at 760 mmHg
Density:0.874g/cm3
Index of Refraction:1.456
PSA:15.27000
Exact Mass:142.14700
LogP:0.87640
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like N-[(1-methylpyrrolidin-3-yl)methyl]ethanamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-[(1-methylpyrrolidin-3-yl)methyl]ethanamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-[(1-methylpyrrolidin-3-yl)methyl]ethanamine Use and application,N-[(1-methylpyrrolidin-3-yl)methyl]ethanamine technical grade,usp/ep/jp grade.
Related News: But it has been barred from that body as Beijing has increased pressure on Taiwan under President Tsai Ing-wen, who is skeptical about closer ties with China. N-[(1-methylpyrrolidin-3-yl)methyl]ethanamine manufacturer “They will now look to re-engage with the FDA to better understand the bar donanemab needs to clear to potentially obtain a more expedited regulatory approval.” N-[(1-methylpyrrolidin-3-yl)methyl]ethanamine supplier Nearly all patients who got the vaccine developed antibodies designed to head off the spread of abnormal tau while leaving healthy tau proteins intact, Novak said. N-[(1-methylpyrrolidin-3-yl)methyl]ethanamine vendor But it has been barred from that body as Beijing has increased pressure on Taiwan under President Tsai Ing-wen, who is skeptical about closer ties with China. N-[(1-methylpyrrolidin-3-yl)methyl]ethanamine factory “They will now look to re-engage with the FDA to better understand the bar donanemab needs to clear to potentially obtain a more expedited regulatory approval.”